This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
DaVita Issues Downbeat '17 View, Hurricanes Affect Q3 Results
by Zacks Equity Research
Hurricanes Harvey and Irma dealt a heavy blow to DaVita's (DVA) operating income in the third quarter. Management's tepid forecast for the full year adds to the concerns.
Here's Why Investors Should Buy Luminex (LMNX) Right Now
by Zacks Equity Research
Luminex (LMNX) continues to grow strong on innovation and product launches.
Quest Diagnostics, Clinical Genomics Ally, Oncology Strong
by Zacks Equity Research
Quest Diagnostics' (DGX) plan to distribute Clinical Genomics' FDA-approved InSure ONE is in line with the company's objective to lead in the high-potential oncology diagnostic market.
Weight Watchers (WTW) to Issue $500M Senior Notes Due 2025
by Zacks Equity Research
Weight Watchers' (WTW) plan to issue senior notes will aid the company in reducing cost of capital.
Medtronic Preliminary Sales Dip Y/Y, Hurricane Blow Lessens
by Zacks Equity Research
Divestiture of certain businesses to Cardinal Health induces year-over-year decline in Medtronic's (MDT) preliminary sales figure. However, impact of Maria is likely to be lighter on the company's finances.
Bio-Rad (BIO) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Balanced growth across all geographical regions as well as many key life science and diagnostics product areas helps Bio-Rad (BIO) to drive the top and bottom line in Q3.
BioTelemetry (BEAT) Q3 Earnings Miss, Revenues Meet Estimates
by Zacks Equity Research
A decline in gross and operating margin was a major drag for BioTelemetry (BEAT) in the third quarter.
Bruker's NANO Grows Strong, MERLIN Buyout Holds Promise
by Zacks Equity Research
Bruker's (BRKR) recent acquisition of Germany-based MERLIN buoys optimism for its growth within MALDI Biotyper business.
AmerisourceBergen (ABC) Rewards Investors With Dividend Hike
by Zacks Equity Research
AmerisourceBergen's (ABC) dividend hike adheres to the company's policy of rewarding stakeholders at regular intervals.
OPKO Health (OPK) Posts Wider-Than-Estimated Loss in Q3
by Zacks Equity Research
OPKO Health (OPK) posts lackluster Q3 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.